Andrew Combs
Insider (Form 4 reporting owner): Chief Chemistry Officer CIK 1825005Name as filed: Combs AndrewIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 29 Sep 2020, bought $269K in 4 open-market purchases of Prelude Therapeutics.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Prelude Therapeutics PRLD | Chief Chemistry Officer | 29 Sep 2020 | 25 Mar 2025 | 4$269K | – |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After purchases | too few trades4 trades | too few trades4 trades | too few trades4 trades |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2025 | 1 | $69K | – | – | $69K |
| 2024 | 1 | $86K | – | – | $86K |
| 2021 | 1 | $95K | – | – | $95K |
| 2020 | 1 | $19K | – | – | $19K |
Every trade
4, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 25 Mar 2025 | Prelude Therapeutics PRLD | Buy | 100,000 | $0.69 | $69K | No | Form 4filed 27 Mar 2025 |
| 20 Dec 2024 | Prelude Therapeutics PRLD | Buy | 63,075 | $1.36 | $86K | No | Form 4filed 26 Dec 2024 |
| 13 Dec 2021 | Prelude Therapeutics PRLD | Buy | 8,000 | $11.86 | $95K | Not stated | Form 4filed 15 Dec 2021 |
| 29 Sep 2020 | Prelude Therapeutics PRLD | Buy | 1,000 | $19.00 | $19K | Not stated | Form 4filed 29 Sep 2020 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.